Eton Pharmaceuticals, Inc. $ETON Stake Trimmed by Sigma Planning Corp

Sigma Planning Corp cut its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 49.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,100 shares of the company’s stock after selling 14,900 shares during the quarter. Sigma Planning Corp owned 0.05% of Eton Pharmaceuticals worth $777,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Sterling Capital Management LLC grew its holdings in shares of Eton Pharmaceuticals by 845.7% during the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after purchasing an additional 795 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in shares of Eton Pharmaceuticals by 159.0% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,852 shares of the company’s stock worth $95,000 after acquiring an additional 1,137 shares in the last quarter. Kings Path Partners LLC bought a new position in Eton Pharmaceuticals in the third quarter valued at approximately $181,000. Robeco Institutional Asset Management B.V. acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $2,368,000. Finally, USA Financial Formulas bought a new stake in Eton Pharmaceuticals during the third quarter worth $62,000. 27.86% of the stock is currently owned by institutional investors.

Insider Activity at Eton Pharmaceuticals

In related news, insider David Krempa sold 4,166 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the transaction, the insider owned 43,381 shares in the company, valued at $2,388,991.67. The trade was a 8.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares of the company’s stock, valued at $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 79,166 shares of company stock valued at $4,809,672. Insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals Stock Down 2.8%

Shares of NASDAQ ETON opened at $52.18 on Friday. The company’s 50 day moving average price is $56.00 and its 200-day moving average price is $35.57. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. Eton Pharmaceuticals, Inc. has a 52-week low of $14.27 and a 52-week high of $66.37. The company has a market capitalization of $1.49 billion, a P/E ratio of 137.32 and a beta of 0.90.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. Equities analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ETON shares. B. Riley Financial reaffirmed a “buy” rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Eton Pharmaceuticals in a research note on Wednesday, October 14th. Craig Hallum reaffirmed a “buy” rating and issued a $78.00 target price on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Finally, Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $71.50.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.